Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

IMvigor130 Study Group

Research output: Contribution to journalArticlepeer-review

536 Scopus citations

Fingerprint

Dive into the research topics of 'Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences